| chronic pain (diagnosis)
Butrans vs Belbuca
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Butrans vs Belbuca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBelbuca has a higher rate of injection site reactions vs Butrans based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Belbuca but not Butrans, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Butrans
Belbuca
At A Glance
Transdermal patch
Every 7 days
Partial mu-opioid agonist
Buccal film
Every 12 hours
Partial opioid agonist
Indications
- chronic pain (diagnosis)
- chronic pain (diagnosis)
Dosing
chronic pain (diagnosis) For opioid-naive patients, initiate with BUTRANS 5 mcg/hour transdermal patch worn for 7 days; for patients on 30-80 mg/day oral morphine equivalents, taper current opioid to <=30 mg/day then initiate at 10 mcg/hour; maximum dose is 20 mcg/hour (one system); titrate no more frequently than every 72 hours in increments of 5, 7.5, or 10 mcg/hour.
chronic pain (diagnosis) 75 mcg buccal film once daily or every 12 hours for opioid-naive patients, titrated in increments of 150 mcg every 12 hours no more frequently than every 4 days to a maximum of 900 mcg every 12 hours; initial dose for opioid-experienced patients: 150 mcg every 12 hours (30-89 mg oral MSE) or 300 mcg every 12 hours (90-160 mg oral MSE).
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity (e.g., anaphylaxis) to buprenorphine or any excipient
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity (e.g., anaphylaxis) to buprenorphine
Adverse Reactions
Most common (>=5%) Nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, application site rash
Serious Life-threatening respiratory depression, addiction/abuse/misuse, interactions with CNS depressants, neonatal opioid withdrawal syndrome, QTc prolongation, anaphylaxis/allergic reactions, hepatotoxicity, seizures, adrenal insufficiency, severe hypotension
Postmarketing Serotonin syndrome, adrenal insufficiency, anaphylaxis, androgen deficiency, hyperalgesia and allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Most common (>=5%) Nausea, constipation, headache, vomiting, fatigue, dizziness, somnolence
Serious Addiction, abuse, and misuse; life-threatening respiratory depression; interactions with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; QTc prolongation; hepatotoxicity; anaphylactic/allergic reactions; seizures
Postmarketing Serotonin syndrome, adrenal insufficiency, anaphylaxis, androgen deficiency, hyperalgesia and allodynia, dental decay (caries, tooth fracture, and tooth loss), hypoglycemia, opioid-induced esophageal dysfunction
Pharmacology
Buprenorphine is a partial agonist at the mu-opioid receptor, an antagonist at kappa-opioid receptors, an agonist at delta-opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors; it produces analgesia and respiratory depression via central opioid receptor modulation, with pharmacodynamic effects including CNS depression, reduced GI motility, and peripheral vasodilation.
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor; it produces analgesia by binding with high affinity to opioid receptors on neurons in the brain and spinal cord and, unlike full opioid agonists, exhibits a dose-ceiling effect on respiratory depression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Butrans
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (10/12)
Belbuca
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Butrans
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Belbuca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Butrans
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Belbuca
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Butrans.
No savings programs available for Belbuca.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ButransView full Butrans profile
BelbucaView full Belbuca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.